Evidence map›Paper›PMID 15812554›Full record

SynthesisBritish journal of cancer2005

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

D D Stocken, M W Büchler, C Dervenis, C Bassi, H Jeekel, J H G Klinkenbijl, K E Bakkevold, T Takada, H Amano, J P Neoptolemos and 1 more

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 6 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 6 syntheses or guidelines pooled it, 359 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pancreatic cancer.BMJ clinical evidence · 2010
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2017
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Radiochemotherapy in Pancreatic Cancer.Current oncology (Toronto, Ont.) · 2024
    Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 7 countries.

D D StockenCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
M W Büchler
C Dervenis
C Bassi
H Jeekel
J H G Klinkenbijl
K E Bakkevold
T Takada
H Amano
J P Neoptolemos
Pancreatic Cancer Meta-analysis Group
Heidelberg University · DEUniversity of Bergen · NOUniversity of Liverpool · GBUniversity of Verona · ITCancer Research UK Clinical Trials Unit · GBRotterdam University of Applied Sciences · NLTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the worldwide evidence of the roles of adjuvant chemoradiation and adjuvant chemotherapy on survival in potentially curative resected pancreatic cancer. Five randomised controlled trials of adjuvant treatment in patients with histologically proven pancreatic ductal adenocarcinoma were identified, of which the four most recent trials provided individual patient data (875 patients). This meta-analysis includes previously unpublished follow-up data on 261 patients. The pooled estimate of the hazard ratio (HR) indicated a 25% significant reduction in the risk of death with chemotherapy (H = 0.75, 95% confidence interval (CI): 0.64, 0.90, P-values(stratified) (Pstrat) = 0.001) with median survival estimated at 19.0 (95% CI: 16.4, 21.1) months with chemotherapy and 13.5 (95% CI: 12.2, 15.8) without. The 2- and 5-year survival rates were estimated at 38 and 19%, respectively, with chemotherapy and 28 and 12% without. The pooled estimate of the HR indicated no significant difference in the risk of death with chemoradiation (HR = 1.09, 95% CI: 0.89, 1.32, Pstrat = 0.43) with median survivals estimated at 15.8 (95% CI: 13.9, 18.1) months with chemoradiation and 15.2 (95% CI: 13.1, 18.2) without. The 2- and 5-year survival rates were estimated at 30 and 12%, respectively, with chemoradiation and 34 and 17% without. Subgroup analyses estimated that chemoradiation was more effective and chemotherapy less effective in patients with positive resection margins. These results show that chemotherapy is effective adjuvant treatment in pancreatic cancer but not chemoradiation. Further studies with chemoradiation are warranted in patients with positive resection margins, as chemotherapy appeared relatively ineffective in this patient subgroup.

Indexed as

Chemotherapy, AdjuvantRadiotherapy, AdjuvantCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedPancreatic NeoplasmsRandomized Controlled Trials as TopicSurvival Analysis

Identifiers

PMID15812554
PMCPMC2361989
OpenAlexW2068707299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.